Showing results (1-10 of 12) with videos related to

Sort By:
Pageof 2
Paediatric Anaesthesia|June 7, 2003
Considerations for anaesthesia in children with haematological malignancy undergoing short proceduresValerie Culshaw, Murray Yule, Ros Lawson
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 5, 2004
Cyclophosphamide metabolism in children with non-Hodgkin's lymphomaS Murray Yule, Lisa Price, Alex D McMahon, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 23, 2014
First-in-human phase I dose escalation study of a second-generation non-ansamycin HSP90 inhibitor, AT13387, in patients with advanced solid tumorsGeoffrey I Shapiro, Eunice Kwak, Bruce J Dezube, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 14, 2003
Phase I and pharmacokinetic study of E7070, a chloroindolyl-sulfonamide anticancer agent, administered on a weekly schedule to patients with solid tumorsChristian Dittrich, Herlinde Dumez, Hilary Calvert, et al.
Investigational New Drugs|July 14, 2005
Human metabolism of [(14)C]indisulam following i.v. infusion in cancer patientsJan-Hendrik Beumer, Michel J X Hillebrand, Dick Pluim, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 17, 2007
A randomized phase II pharmacokinetic and pharmacodynamic study of indisulam as second-line therapy in patients with advanced non-small cell lung cancerDenis C Talbot, Joachim von Pawel, Emma Cattell, et al.
Clinical Lymphoma, Myeloma & Leukemia|December 21, 2013
A phase I and pharmacodynamic study of AT9283, a small-molecule inhibitor of aurora kinases in patients with relapsed/refractory leukemia or myelofibrosisJames Foran, Farhad Ravandi, William Wierda, et al.
Rapid Communications in Mass Spectrometry : RCM|November 2, 2004
Quantitative determination of the novel anticancer drug E7070 (indisulam) and its metabolite (1,4-benzenedisulphonamide) in human plasma, urine and faeces by high-performance liquid chromatography coupled with electrospray ionization tandem mass spectrometryJan Hendrik Beumer, Hilde Rosing, Michel J X Hillebrand, et al.
European Journal of Cancer (Oxford, England : 1990)|May 9, 2016
Dose-escalation study of a second-generation non-ansamycin HSP90 inhibitor, onalespib (AT13387), in combination with imatinib in patients with metastatic gastrointestinal stromal tumourAndrew J Wagner, Mark Agulnik, Michael C Heinrich, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 23, 2004
A phase II clinical and pharmacodynamic study of E7070 in patients with metastatic, recurrent, or refractory squamous cell carcinoma of the head and neck: modulation of retinoblastoma protein phosphorylation by a novel chloroindolyl sulfonamide cell cycle inhibitorRobert I Haddad, Lisa J Weinstein, Tad J Wieczorek, et al.
Pageof 2